17 results
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:17pm
in which we operate to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials
424B5
ZYME
Zymeworks Inc.
3 May 24
Prospectus supplement for primary offering
4:11pm
incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential
8-K
EX-10.1
aucq 60erydaoepxe
16 May 23
Entry into a Material Definitive Agreement
8:30am
424B5
z0by7h
8 May 23
Prospectus supplement for primary offering
5:19pm
424B5
6wesqh
8 May 23
Prospectus supplement for primary offering
5:18pm
8-K
EX-99.1
46k4he5v8y
21 Dec 22
Jazz Pharmaceuticals and Zymeworks Announce Jazz has Confirmed Opt-in and Advances Partnership for Zanidatamab
8:37am
424B5
s0pc57t8 xf4r
9 Nov 22
Prospectus supplement for primary offering
4:29pm
10-Q
7w5e44qry2c356
8 Nov 22
Quarterly report
4:09pm
424B5
yo4s589766f
21 Oct 22
Prospectus supplement for primary offering
4:16pm
8-K
EX-99.1
dwcy0
19 Oct 22
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
6:26am
424B5
66iz635 iql4nqw2
13 Oct 22
Prospectus supplement for primary offering
4:56pm
- Prev
- 1
- Next